metaEvidence - mapping review

meta|evidence oncology

Living systematic review and meta-analysis

limited stage SCLC (ls-SCLC)
limited stage SCLC (ls-SCLC) - maintenance (M) 1
limited stage SCLC (ls-SCLC) - 2nd Line (L2)
melanoma (ML)

versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs alkylating agents
vs dacarbazine
vs fotemustine
vs Standard of Care (SoC)
vs placebo plus SoC
vs immune chekpoint inhibitors
vs anti-CTLA-4
vs ipilimumab based treatment
vs ipilimumab alone
vs Ipilimumab (10 mg/kg)
vs ipilimumab plus dacarbazine
vs ipilimumab followed by nivolumab
vs anti-PD-(L)1
vs nivolumab based treatment
vs nivolumab alone
vs nivolumab followed by ipilimumab
vs pembrolizumab based treatment
vs pembrolizumab alone
vs Immune checkpoint association
vs nivolumab plus ipilimumab
vs Immunostimulant
vs interferon alpha
vs vaccine
vs gp100
vs non active control
vs placebo

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

graph table EGM comparisons

click on circles to display study description...

IMspire-170, 2020 NCT03273153

atezolizumab plus cometinib (n=222) vs. pembrolizumab alone (n=224)

randomized controlled trial

Studied treatment

cometinib plus atezolizumab
cobimetinib (60 mg once daily, days 1-21) plus intravenous atezolizumab (840 mg, days 1 plus 15) in 28-day cycles

Control treatment

pembrolizumab
intravenous pembrolizumab (200 mg every 3 weeks)

Dose reductions for atezolizumab or pembrolizumab were not permitted.

Patients

mML - L1 - BRAF wild

Method

open label

multicenter

P3/ two sided and no interim analysis. Hierarchical testing procedure (PFS(IRC) then OS then ORR)

Remark

Cobimetinib plus atezolizumab did not improve PFS compared with pembrolizumab monotherapy in patients with BRAF mutation

powered by vis.js Network